In this study, we explored the molecular mechanisms for the BTZ-resistance in MCL with respect to BCR signaling and assessed the efficacy of dasatinib as a therapeutic approach for BTZ-resistant MCL patients. Here, BCR is linked to mantle cell lymphoma.